Why the study?
Does clopidogrel 300 mg loading dose followed by 75 mg/day provide adequate platelet inhibition in patients after percutaneous coronary intervention and stent implantation?
Population
57 patients after percutaneous coronary intervention and stent implantation
Design
Cohort
Follow-up
median 5 days
Authors
Loading...
Clopidogrel nonresponsiveness after PCI may reflect metabolization differences rather than receptor mutations; leaves open personalized dosing strategies pending prospective validation.
Does clopidogrel 300 mg loading dose followed by 75 mg/day provide adequate platelet inhibition in patients after percutaneous coronary intervention and stent implantation?
A significant proportion of patients (17.5%) exhibit inadequate responsiveness to standard clopidogrel dosing after coronary stenting, likely due to individual differences in metabolization rather than P2Y12 receptor mutations.
Schnurr et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: